<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=348185225613720&amp;ev=PageView&amp;noscript=1">
Skip to content

ON-DEMAND WEBINAR

Precision Proteomics: How to Enable Biomarker Identification in Health and Disease

Jointly organized by Azenta Life Sciences and Olink

Agenda:

  • Review of Olink's Proteomics platform
  • Use cases for actionable biomarker discovery
  • Precision Proteomics as a tool
  • Specific ways to improve health outcomes for patients with cancer, inflammatory or age-related diseases

Download Now

Meet the Presenter

Speaker ID
Michael Förster, Ph.D.
Scientific Director, Oncology and Rare Disease

Michael Förster joined Olink’s Scientific Affairs team as Director Oncology and Rare Disease. He completed his PhD on autoimmune disease genetics at Karolinska Institute and moved to McGill University for a postdoc investigating the link between primary immunodeficiency, hematopoiesis and the development of hematological malignancies.

He left academia for a stint at the Fraunhofer Society to manage projects in liquid biopsy based cancer diagnostics and CAR T cell therapy and more recently worked for Azenta Life Sciences as Scientific Liaison for biospecimen procurement and genomics services.

Olink-Logotype_Black

Impacting patient's health with Proteomics as a tool for biomarker identification

In this scientific seminar, we will discuss Olink’s proteomics platform and present use cases for actionable biomarker discovery – underscoring the role of precision proteomics as a tool to improve health outcomes for patients with cancer, inflammatory or age-related diseases.

Olink Proteomics, a Swedish company with strong global presence, enables high-plex protein biomarker discovery and development with unparalleled specificity and sensitivity.

Olink’s platform currently has the ability to robustly measure ~3,000 targets. It’s been wide adopted due to its scalability and actionability to help answer research questions aiming to elucidate signaling pathways in health and diseases, novel mechanisms of drug action or as a tool to identify biomarker signatures with a prognostic/predictive value.

With its expanding protein library, covering all major biological pathways and >600 known drug targets Olink assays have been applied in common complex disorders such as cancer, inflammatory and metabolic diseases.